These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 11023348)

  • 1. [HIV and antiretroviral therapy: in every 3rd patient a virus rebound takes place].
    Kunde K
    Dtsch Med Wochenschr; 2000 Aug; 125(33):A10. PubMed ID: 11023348
    [No Abstract]   [Full Text] [Related]  

  • 2. Residual HIV-1 disease in the era of highly active antiretroviral therapy.
    Pomerantz RJ
    N Engl J Med; 1999 May; 340(21):1672-4. PubMed ID: 10341281
    [No Abstract]   [Full Text] [Related]  

  • 3. Antiretrovirals for the heavily experienced patient: hefty plans to holidays.
    Martinez LJ
    Res Initiat Treat Action; 1999 Oct; 5(4):5-8. PubMed ID: 11366942
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IL-2 taken to HAART.
    Gilden D
    GMHC Treat Issues; 1999 Feb; 13(2):4-6. PubMed ID: 11366116
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment interruptions in HIV-infected subjects.
    Bongiovanni M; Casana M; Tincati C; d'Arminio Monforte A
    J Antimicrob Chemother; 2006 Sep; 58(3):502-5. PubMed ID: 16816398
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [How HIV treatment can be simplified. "Once daily" as starter therapy is effective].
    Wepner U
    MMW Fortschr Med; 2009 Apr; 151(18):80-1. PubMed ID: 19769085
    [No Abstract]   [Full Text] [Related]  

  • 7. Virological characterization of patients treated early is able to control HIV-1 replication after multiple cycles of structured therapy interruption.
    Rozera G; Abbate I; D'Offizi G; Corpolongo A; Narciso P; Vlassi C; Martini F; Calcaterra S; Capobianchi MR
    J Med Virol; 2007 Aug; 79(8):1047-54. PubMed ID: 17597482
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human immunodeficiency virus type 1 quasi species that rebound after discontinuation of highly active antiretroviral therapy are similar to the viral quasi species present before initiation of therapy.
    Imamichi H; Crandall KA; Natarajan V; Jiang MK; Dewar RL; Berg S; Gaddam A; Bosche M; Metcalf JA; Davey RT; Lane HC
    J Infect Dis; 2001 Jan; 183(1):36-50. PubMed ID: 11106537
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [HIV: "big bang" in view].
    Vernazza PL
    Schweiz Med Wochenschr; 1997 Dec; 127(51-52):2129-31. PubMed ID: 9487573
    [No Abstract]   [Full Text] [Related]  

  • 10. Understanding the principles of anti-HIV drug therapy.
    Horn T
    Surviv News (Atlanta Ga); 2001 Jul; ():13. PubMed ID: 11683014
    [No Abstract]   [Full Text] [Related]  

  • 11. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy.
    Steingrover R; Pogány K; Fernandez Garcia E; Jurriaans S; Brinkman K; Schuitemaker H; Miedema F; Lange JM; Prins JM
    AIDS; 2008 Aug; 22(13):1583-8. PubMed ID: 18670217
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stimulation of HIV-specific cellular immunity by structured treatment interruption fails to enhance viral control in chronic HIV infection.
    Oxenius A; Price DA; Günthard HF; Dawson SJ; Fagard C; Perrin L; Fischer M; Weber R; Plana M; García F; Hirschel B; McLean A; Phillips RE
    Proc Natl Acad Sci U S A; 2002 Oct; 99(21):13747-52. PubMed ID: 12370434
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [HIV eradication--facts and fiction].
    Jaeger H; Wolf E
    MMW Fortschr Med; 2008 Apr; 150 Spec No 1():72-3. PubMed ID: 19024923
    [No Abstract]   [Full Text] [Related]  

  • 15. Replication capacity, biological phenotype, and drug resistance of HIV strains isolated from patients failing antiretroviral therapy.
    Nicastri E; Sarmati L; d'Ettorre G; Palmisano L; Parisi SG; Uccella I; Rianda A; Concia E; Vullo V; Vella S; Andreoni M
    J Med Virol; 2003 Jan; 69(1):1-6. PubMed ID: 12436471
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Viral dynamics in the course of HIV-1 infection: pathogenetic features and new therapeutic prospects].
    Marcello A; Giacca M
    Pathologica; 2000 Aug; 92(4):291-3. PubMed ID: 11029891
    [No Abstract]   [Full Text] [Related]  

  • 17. Adherence to antiretroviral therapy: how much is enough?
    Gulick RM
    Clin Infect Dis; 2006 Oct; 43(7):942-4. PubMed ID: 16941381
    [No Abstract]   [Full Text] [Related]  

  • 18. HAART version 2.0.
    Huff B
    GMHC Treat Issues; 2002 Mar; 16(3):1-4. PubMed ID: 12004795
    [No Abstract]   [Full Text] [Related]  

  • 19. [Approval of a new nucleoside. Component of complete once daily regimen].
    MMW Fortschr Med; 2004 Apr; 146 Spec No 1():91. PubMed ID: 15373067
    [No Abstract]   [Full Text] [Related]  

  • 20. Stopping antiretroviral therapy means viral rebound...usually.
    AIDS Clin Care; 1999 Jul; 11(7):60-1. PubMed ID: 11366436
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.